Compare Incyte Corporation (INCY) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United Microelectronics Corp — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while United Microelectronics Corp trades at $21.15 (market cap $51.00B). The key difference: United Microelectronics Corp is far larger — about 2.2× Incyte Corporation's market cap, and United Microelectronics Corp pays a 2.03% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | UMC | |
|---|---|---|
Market Cap | $23.11B | $51.00B |
Sector | Health | Technology |
52-Week High | $118.52 | $28.02 |
52-Week Low | $67.38 | $6.58 |
Enterprise Value | $19.13B | $48.57B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
UMC trades at $21.19, down 0.28% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains a net income margin of 20.25%. Recent news highlights mass production of silicon photonics ICs and strong June 2026 sales growth of 22.85% year-over-year.
Outlook is supported by earnings beats and specialty technology demand, but risks include valuation above sector peers and competitive pressures. Analysts are mixed with 26.67% buy ratings, suggesting cautious optimism amid solid execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
